DCAF4L2 overexpression and other abnormalities of NF-ΚB signaling shown in Table 1 may be mutually complementary for development and progression of NASH-related HCCs, and DCAF4L2 may therefore be a candidate therapeutic target in HCCs. This evidence concerns the gene DCAF4L2 and metabolic dysfunction-associated steatohepatitis.